Development Issues Clause Samples

The 'Development Issues' clause defines how problems or obstacles encountered during a project's development phase are identified, communicated, and addressed by the parties involved. Typically, this clause outlines procedures for reporting issues, timelines for response or resolution, and responsibilities for each party in managing such challenges. By establishing a clear process for handling development-related problems, the clause helps prevent misunderstandings, ensures timely resolution, and keeps the project on track.
Development Issues. For purposes of commercial development reporting, the addresses of the Parties shall be as follows: If to DIVERSA: Diversa Corporation ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Attention: ▇▇▇ ▇. Short, PhD Chief Executive Officer Telephone: ▇▇▇-▇▇▇-▇▇▇▇ Facsimile: ▇▇▇-▇▇▇-▇▇▇▇ If to DOW: The Dow Chemical Company ▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Attention: ▇▇▇▇▇▇▇ ▇▇▇▇ Biomaterials Platform Director [****]
View SourceView Similar (2)
Development Issues. REACH is aware of no identifiable issue(s) that would preclude development of the Project or REACH’s ability to cause the Partnership to obtain sufficient financing for the construction or permanent ownership of the Project.
View Source
Development Issues. At the Cancun Ministerial Conference, all developmental issues were categorized into one group and this group covered special and differential treatment (S&D); implementation; technical assistance; least-developed countries; commodity issues; small economies; trade, debt and finance; and trade and technology transfer. As regards the special and differential treatment (S&D) and implementation-issues, the core development elements of the Doha Declaration, only instructed Members to continue the work that has been underway since early 2002 and reiterated earlier commitments with regard to technical assistance and the work programme for least-developed countries (LDC’s).
View Source
Development Issues. 33. At the Cancun Ministerial Conference, all developmental issues were categorized into one group and this group covered special and differential treatment (S&D); implementation; technical assistance; least-developed countries; commodity issues; small economies; trade, debt and finance; and trade and technology transfer. 34. While negotiating these issues in the Conference, the Facilitator Mukhisa Kituyi (Kenya) highlighted two issues which require further work: special and differential treatment and implementation. On the issue of special and differential treatment, differences remain among the Members as to whether the current package of 24 agreed proposals is acceptable for now. A number of developing countries believe that there is little economic value in the current package. Other developing countries felt that though there is some value, more should be achieved. 35. As regards implementation, a group of developing countries presented new language for the negotiation text. This text calls for: the negotiating groups to address as a matter of priority implementation issues dealt by them; a negotiating group to address all the remaining outstanding implementation issues; and decisions to be adopted by March 2004. Some developed countries delegations were of the view that they were not ready to establish a negotiating group on implementation. However, nothing concrete was achieved out of the Cancun Ministerial Conference.
View Source
Development Issues. ▇▇▇ is aware of no identifiable issue(s) that would preclude development of the Project or AVA’s ability to obtain sufficient financing for the construction or permanent ownership of the Project.
View Source
Development Issues. For purposes of commercial development reporting, the addresses of the Parties shall be as follows: If to DIVERSA: Diversa Corporation ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Attention: ▇▇▇ ▇. Short, PhD Chief Executive Officer Telephone: ▇▇▇-▇▇▇-▇▇▇▇ Facsimile: ▇▇▇-▇▇▇-▇▇▇▇ If to the LLC: New Venture LLC ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ Attention: Telephone: Facsimile:
View Source
Development Issues. DIG is aware of no identifiable issue(s) that would preclude development of the Project or DIG’s ability to obtain sufficient financing for the construction or permanent ownership of the Project.
View Source
Development Issues 
View SourceView Similar (4)

Related to Development Issues

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in ▇▇▇▇▇, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.